Search results for "glycoprotein"

showing 10 items of 852 documents

Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease

2004

Recent studies demonstrated that glycoprotein (GP) IIb/IIIa receptor antagonists improve endothelial dysfunction of forearm resistance vessels in patients with stable coronary artery disease. However, it remains unclear whether these findings can be extended to the conductance vessel level. In this study, we aimed to evaluate the acute effect of tirofiban on endothelial function of arterial conductance vessels in patients undergoing percutaneous coronary intervention (PCI). Endothelial function was examined by ultrasonographic measurement of flow-mediated vasodilation (FMD) of the brachial artery. Endothelium-independent vasodilation was determined in response to nitroglycerin. Sixty-six pa…

Malemedicine.medical_specialtyBrachial ArteryEndotheliummedicine.medical_treatmentCoronary Artery DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexCoronary artery diseaseAngioplastymedicine.arteryInternal medicinemedicineHumanscardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbusiness.industryPercutaneous coronary interventionTirofibanmedicine.diseasemedicine.anatomical_structureTirofibanConventional PCIcardiovascular systemCardiologyTyrosineFemaleEndothelium VascularCardiology and Cardiovascular Medicinebusinessmedicine.drugThe American Journal of Cardiology
researchProduct

Fetuin-B, a liver-derived plasma protein is essential for fertilization.

2013

SummaryThe zona pellucida (ZP) is a glycoprotein matrix surrounding mammalian oocytes. Upon fertilization, ZP hardening prevents sperm from binding to and penetrating the ZP. Here, we report that targeted gene deletion of the liver-derived plasma protein fetuin-B causes premature ZP hardening and, consequently, female infertility. Transplanting fetuin-B-deficient ovaries into wild-type recipients restores fertility, indicating that plasma fetuin-B is necessary and sufficient for fertilization. In vitro fertilization of oocytes from fetuin-B-deficient mice only worked after rendering the ZP penetrable by laser perforation. Mechanistically, fetuin-B sustains fertility by inhibiting ovastacin,…

Malemedicine.medical_specialtyCell Membrane Permeabilitymedicine.medical_treatmentmacromolecular substancesFertilization in VitroBiologyGeneral Biochemistry Genetics and Molecular BiologyMiceHuman fertilizationPregnancyInternal medicinemedicineAnimalsZona pellucidaMolecular BiologyZona Pellucidachemistry.chemical_classificationProteaseOvaryGene Expression Regulation DevelopmentalEmbryoCell BiologyEmbryo TransferEmbryo MammalianSpermFetuinSpermatozoaFetuin-BRecombinant ProteinsCell biologyEnzyme ActivationMice Inbred C57BLmedicine.anatomical_structureEndocrinologychemistryFertilizationMetalloproteasesOocytesGameteFemaleGlycoproteinInfertility FemaleDevelopmental BiologyDevelopmental cell
researchProduct

Fetuin-A is Associated to Serum Calcium and AHSG T256S Genotype but Not to Coronary Artery Calcification

2015

Vascular calcification has been recently associated to an increased cardiovascular risk and mortality. In few studies, Fetuin-A showed an association to coronary artery calcification (CAC), although the physiopathological mechanism underlying this association has not been fully established yet. Seventy-four patients with one or more cardiovascular risk factor and asymptomatic for coronary vasculopathy were included in the study. CAC was evaluated by Agatston score. Serum Fetuin-A levels were determined by ELISA. Molecular analysis of AHSG T256S gene variant (rs4918) was performed by PCR-RFLP. Serum Fetuin-A was correlated to serum calcium (r = 0,321; P = 0,018), but not to serum phosphorous…

Malemedicine.medical_specialtyGenotypealpha-2-HS-Glycoprotein030232 urology & nephrologychemistry.chemical_elementCoronary artery calcification030204 cardiovascular system & hematologyBiologyCalciumGastroenterologyAsymptomaticPolymorphism Single NucleotideCoronary artery diseaseBiochemistryCoronary artery disease03 medical and health sciences0302 clinical medicineGeneticInternal medicineGenotypeGeneticsmedicineHumansRisk factorAmplified Fragment Length Polymorphism AnalysisVascular CalcificationMolecular BiologyEcology Evolution Behavior and SystematicsAgedGeneral MedicineMiddle AgedSerum calciummedicine.diseaseFetuinCoronary VesselsFetuin-AEndocrinologySettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicachemistryAHSGCalciumFemalemedicine.symptomSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioAgatston scoreSettore MED/36 - Diagnostica Per Immagini E Radioterapiaalpha-2-HS-glycoprotein
researchProduct

Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils

2013

Atherosclerosis is a chronic inflammatory process involving polymorphonuclear neutrophils (PMN) and formation of reactive oxygen species (ROS). The aim of the present study was to investigate the phenotype of inflammatory cells in regard to the expression of triggering receptor expressed on myeloid cells (TREM)-1 and its soluble form (sTREM-1) as well as its relationship with oxidative stress in peripheral artery disease (PAD) patients.In total 90 patients with PAD (N = 30 intermittent claudication (IC)300 m absolute walking distance, N = 30 IC300 m absolute walking distance, N = 30 critical limb ischaemia (CLI)) and 30 control persons were included. ROS formation was measured at basal or s…

Malemedicine.medical_specialtyNeutrophilsWalkingmedicine.disease_causeMonocytesFlow cytometryPeripheral Arterial DiseaseBasal (phylogenetics)IschemiaRisk FactorsInternal medicinePrevalencemedicineHumansReceptors ImmunologicReceptorAgedWhole bloodchemistry.chemical_classificationReactive oxygen speciesMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industryMiddle AgedAtherosclerosisFlow CytometryPhenotypeTriggering Receptor Expressed on Myeloid Cells-1Intermittent claudicationOxidative StressEndocrinologychemistryImmunologyDisease ProgressionFemaleEndothelium Vascularmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessBiomarkersOxidative stressAtherosclerosis
researchProduct

Fetuin-A and CD40L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory vari…

2009

Abstract Introduction Accumulating evidence suggests that inflammation plays an important role in the acute phase of ischemic stroke. CD40 L is a well recognized atherosclerotic inflammatory marker, whereas recent evidence suggests a pro-inflammatory role of Fetuin-A. To analyze the role of an inflammatory marker such as CD40 L and of a candidate pro-inflammatory marker such as Fetuin-A in acute stroke we evaluated their serum levels in subjects with acute ischemic stroke and their possible association with other laboratory and clinical variables. Materials and methods We enrolled 107 consecutive patients with a diagnosis of acute ischemic stroke admitted to the Internal Medicine Department…

Malemedicine.medical_specialtyPathologyalpha-2-HS-GlycoproteinCD40 LigandGastroenterologyBrain IschemiaCentral nervous system diseaseBrain ischemiaInternal medicineDiabetes mellitusWhite blood cellmedicineHumansStrokeAgedAged 80 and overbusiness.industryCerebral infarctionVascular diseaseBlood ProteinsMiddle Agedmedicine.diseaseStrokemedicine.anatomical_structureAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessFetuin-A CD40L strokealpha-2-HS-glycoprotein
researchProduct

Mass Concentration of Plasma Phospholipid Transfer Protein in Normolipidemic, Type IIa Hyperlipidemic, Type IIb Hyperlipidemic, and Non–Insulin-Depen…

1999

Abstract —Mean plasma phospholipid transfer protein (PLTP) concentrations were measured for the first time by using a competitive enzyme-linked immunosorbent assay. PLTP mass levels and phospholipid transfer activity values, which were significantly correlated among normolipidemic plasma samples ( r =0.787, P <0.0001), did not differ between normolipidemic subjects (3.95±1.04 mg/L and 575±81 nmol · mL −1 · h −1 , respectively; n=30), type IIa hyperlipidemic patients (4.06±0.84 mg/L and 571±43 nmol · mL −1 · h −1 , respectively; n=36), and type IIb hyperlipidemic patients (3.90±0.79 mg/L and 575±48 nmol · mL −1 · h −1 , respectively; n=33). No significant correlations with plasma lipid p…

Malemedicine.medical_specialtyPhospholipidEnzyme-Linked Immunosorbent AssayHyperlipidemiasCarbohydrate metabolismchemistry.chemical_compoundReference ValuesPhospholipid transfer proteinInternal medicineDiabetes mellitusCholesterylester transfer proteinBlood plasmamedicineHumansPhospholipid Transfer ProteinsGlycoproteinsbiologyChemistryImmune SeraOsmolar ConcentrationMembrane ProteinsLipid metabolismmedicine.diseaseLipidsCholesterol Ester Transfer ProteinsType iibEndocrinologyDiabetes Mellitus Type 2biology.proteinFemaleCarrier ProteinsCardiology and Cardiovascular MedicineArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Spatiotemporal distribution of gp130 cytokines and their receptors after status epilepticus: comparison with neuronal degeneration and microglial act…

2003

Although numerous studies have demonstrated the neurotrophic capacity of gp130 cytokines, it remains unclear whether endogenously expressed cytokines actually function in a direct neuromodulatory manner. Therefore, using the lithium-pilocarpine status epilepticus model, we performed a detailed in situ hybridization time-course study of five gp130 cytokines (interleukin [IL]-6, leukemia inhibitory factor [LIF], IL-11, oncostatin-m [OSM], and ciliary neurotrophic factor), gp130, and the receptors of the cytokines we found to be induced (IL-6 receptor [IL-6R], LIF receptor [LIF-R], and IL-11 receptor [IL-11R]). Additionally, to further understand the regulation of these cytokines, we compared …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBiologyHippocampal formationHippocampusRats Sprague-DawleyStatus EpilepticusInternal medicinemedicineAnimalsReceptors CytokineReceptorMicrogliaGeneral NeuroscienceDentate gyrusGlycoprotein 130Granule cellRatsmedicine.anatomical_structureEndocrinologyCytokineNerve DegenerationCytokinesMicrogliaLeukemia inhibitory factorSignal TransductionNeuroscience
researchProduct

The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.

2012

Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP).A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months.Urinary tubular markers at baseline and after each treatment period (ELISA),…

Malemedicine.medical_specialtyUrinary systemClinical BiochemistryUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesurologic and male genital diseasesFatty Acid-Binding ProteinsDiabetic nephropathyRenin-Angiotensin SystemIrbesartanLipocalin-2Internal medicineDiabetes mellitusProto-Oncogene ProteinsmedicineHumansDiabetic NephropathiesHepatitis A Virus Cellular Receptor 1AgedMembrane Glycoproteinsurogenital systembusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLipocalinsEndocrinologyKidney TubulesAlbuminuriaReceptors VirusMicroalbuminuriaFemalemedicine.symptombusinessmedicine.drugAcute-Phase ProteinsScandinavian journal of clinical and laboratory investigation
researchProduct